Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety

Significant safety signals in dose-ranging trial may end drug's future in CV prevention

Related Keywords

University Of Washington ,Washington ,United States ,Seattle ,Eugene Yang ,Eileen Handberg ,Ppamerican College Of Cardiology ,Pfizer ,University Of Florida ,Ionis Pharmaceuticals ,Prevention Council ,